Isbn: 9789819634552 - rna-based cancer therapeutics: techniques, applications and challenges in prognosis (2 Ergebnisse)

ISBN
Mit der Detailsuche verfeinern

Optimieren Sie Ihre Suche

  • Bücher (2)

  • Neu (2)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

    • Sprache: Englisch

      Verlag: Springer, 2025

      9819634555 / 9789819634552

      • Hardcover

      Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 226,79

      EUR 13,15 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: Mehr als 20 verfügbar

      Zustand: New. In.

    • Sprache: Englisch

      Verlag: Springer, 2025

      9819634555 / 9789819634552

      • Hardcover

      Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 253,02

      EUR 30,50 Versand 
      Versand von Deutschland nach USA

      Anzahl: 1 verfügbar

      Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - By consistently dedicating efforts to multi-omic and other high-throughput technologies, it is expected that RNA therapies will have a vital role in future personalized medicine approaches for cancer therapy. Within this framework, analyzing the genetic sequence of a patient's tumor would allow for the detection of crucial driver mutations or changes that cause resistance to drugs. These mutations may then be targeted with RNA therapies that are particularly designed to treat those particular variations. Recent clinical trials have shown that RNA-based therapies hold great potential for treating several illnesses. However, further investigations are required to improve the delivery materials and understand the RNA alterations linked to these groundbreaking drugs, in order to facilitate their integration into clinical practice. Ideally, these therapeutic substances would be specifically administered to the tumor cells of interest using a targeted delivery agent. In this hypothetical situation, the choice of medications for cancer patients would differ depending on the precise abnormalities detected in each person, potentially including inhibitors that target circuits known to cause resistance to treatments. However, doing a more thorough assessment of the challenges and potential benefits discussed in each chapter would enhance the capacity to critically analyze this rapidly evolving field of therapies. This book largely examines the latest developments and clinical studies related to RNA-based medications, while also examining the challenges and future possibilities linked with them. This method shows potential for greatly improving the prognosis of cancer patients.